FRI0675 Rabiopred, an innovative theranostic tool to assist clinicians select an optimal anti-tnf al...
FRI0675 Rabiopred, an innovative theranostic tool to assist clinicians select an optimal anti-tnf alpha biological therapy for rheumatoid arthritis patients
About this item
Full title
Author / Creator
Schordan, E. , Coq, M. , AIT ABBI NAZI, S. , Mehdi, M. , Firat, H. , Arber, N. , Breuil, V. , A.-Demoux, L. , Gül, A. , J.-Gottenberg, E. , Hatemi, G. , Huizinga, T. , Inanç, N. , Vencovský, J. and Jorgensen, C.
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Background:TNF alpha blockers form 2nd line treatment choice for Rheumatoid Arthritis (RA) patients. Up to 30% of RA patients do not respond to TNF alpha blockers for unknown reasons, causing a significant impact on patients’ outcome and healthcare industry. Therefore, there is an unmet need for a tool to predict treatment response that could help...
Alternative Titles
Full title
FRI0675 Rabiopred, an innovative theranostic tool to assist clinicians select an optimal anti-tnf alpha biological therapy for rheumatoid arthritis patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2071200029
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2071200029
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2018-eular.6236
